PAOLA-1 Phase 3 Trial – LYNPARZA® (olaparib) + Bevacizumab for Advanced Ovarian Cancer
Efficacy of maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed, advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial - Gynecologic Oncology
Rationale for combination PARP inhibitor and antiangiogenic treatment in advanced epithelial ovarian cancer: A review - Gynecologic Oncology
Olaparib Plus Bevacizumab Combination Expands Options in HRD+ Cancer
PARP-inhibitors in epithelial ovarian cancer: Actual positioning and future expectations - Cancer Treatment Reviews
PARPi in OC - Ovarian Cancer PARPi Therapy - Module - PARP Inhibitors in Ovarian Cancer - Oncology - Clinical Care Options
SOLO1 and PAOLA-1 study designs. a CR in SOLO1 included both patients... | Download Scientific Diagram
FDA starts speedy review of Lynparza plus Avastin in ovarian cancer - PMLiVE
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer | NEJM
PAOLA-1 Phase 3 Trial – LYNPARZA® (olaparib) + Bevacizumab for Advanced Ovarian Cancer
PAOLA-1 : Randomized, Double-Blind, Phase III Trial of Olaparib vs. Placebo in Patients with Advanced FIGO Stage IIIB – IV Hig
18 Efficacy of maintenance olaparib plus bevacizumab by biomarker status in clinical higher- and lower-risk patients with newly diagnosed, advanced ovarian cancer in the PAOLA-1 trial | International Journal of Gynecologic Cancer
PAOLA-1 Phase 3 Trial – LYNPARZA® (olaparib) + Bevacizumab for Advanced Ovarian Cancer
Population-adjusted indirect treatment comparison of the SOLO1 and PAOLA-1/ENGOT-ov25 trials evaluating maintenance olaparib or bevacizumab or the combination of both in newly diagnosed, advanced BRCA-mutated ovarian cancer - ScienceDirect
Progress in the Management of Ovarian Cancer: Evolution Over 40 Years - ppt download
Population-adjusted indirect treatment comparison of the SOLO1 and PAOLA-1/ENGOT-ov25 trials evaluating maintenance olaparib or bevacizumab or the combination of both in newly diagnosed, advanced BRCA-mutated ovarian cancer - ScienceDirect
PAOLA-1: Combination Maintenance Therapy in Ovarian Cancer
Multimodal Treatment of Primary Advanced Ovarian Cancer | Anticancer Research
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer | NEJM
18 Efficacy of maintenance olaparib plus bevacizumab by biomarker status in clinical higher- and lower-risk patients with newly diagnosed, advanced ovarian cancer in the PAOLA-1 trial | International Journal of Gynecologic Cancer
PAOLA-1 Phase 3 Trial – LYNPARZA® (olaparib) + Bevacizumab for Advanced Ovarian Cancer
PAOLA-1 Phase 3 Trial – LYNPARZA® (olaparib) + Bevacizumab for Advanced Ovarian Cancer
Breakthrough from PAOLA1 GINECO/ENgOT-ov25 trial
